Drug Trial Radar · NCT05714969
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Jul 21, 2023
Primary completion
Apr 16, 2026
Study completion Apr 16, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response in Part 1 or platelet response in Part 2. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.
Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755Biological
TAK-755 IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESIs) After Receiving any Dose of Investigational Product (IP)Time frame: Through study completion, approximately 12 weeks
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
University of Florida - Shands
Gainesville, Florida
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Minnesota Clinical Research Unit
Minneapolis, Minnesota
Rutgers University
New Brunswick, New Jersey
Weill Cornell
New York, New York
Duke University Medical Center
Durham, North Carolina
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina
Ohio State University
Columbus, Ohio
University of Utah Health Sciences Center
Salt Lake City, Utah
Versiti Wisconsin, Inc.
Milwaukee, Wisconsin
AKH - Medizinische Universitat Wien
Vienna, Austria
General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, Greece
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy
Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
Torino, Italy
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
Hospital de Cruces
Barakaldo, Vizcaya, Spain
University College London Hospital
London, Greater London, United Kingdom
Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.